HLA-DMA and cardiovascular disorder: Notably, along with their cardioprotective and immunomodulatory effects, MSCs or MSCev are broadly used in allogenic settings as a recommended therapeutic option for cardiovascular diseases due to their lack of HLA class II, such as HLA-DP, HLA-DM, HLA-DQ, and HLA-DR (36, 37).